Stylus Medicine Launches to Develop Precision, In Vivo Genetic Medicines and Unlock the Full Potential of CAR-T Therapy

May 13, 2025

CAMBRIDGE, Mass. – Stylus Medicine, Inc. (“Stylus”), a biotechnology company dedicated to developing transformative in vivo genetic medicines, today emerges from stealth with $85 million in financing. Stylus’ funding includes a $45 million Series A extension financing with participation from RA Capital Management, Khosla Ventures, and six new investors including Chugai Venture Fund, Eli Lilly and Company, and Johnson & Johnson Innovation – JJDC. This financing follows a $40 million Series A investment from founding investors RA Capital and Khosla Ventures.